Jindřich Špinar, Jiří Vítovec, Lenka Špinarová
Authors give an overview of new knowledge from large clinical studies of last two years. ACE inhibitors have been the golden standard of the treatment, and up to that, their indication involves the secondary prevention of ischaemic heart disease. The efficiency of angiotensin II receptors 1 blockers is comparable, but not more efficient. Combination of both of them is likely more beneficial in long-term heart failure, but it not after myocardial infarction. There were found new information about beta-blockers, where carvedilol seems to be the most beneficial. New information about anticoagulant and antiagregation therapy is also interesting, though exact rules proved by large clinical studies are missing. Some new drugs such as dual inhibitors or endothelin blockers did not fulfil the expectations, and there are many other substances still in development.